KR102191695B1 - 전이 억제제 - Google Patents

전이 억제제 Download PDF

Info

Publication number
KR102191695B1
KR102191695B1 KR1020157031658A KR20157031658A KR102191695B1 KR 102191695 B1 KR102191695 B1 KR 102191695B1 KR 1020157031658 A KR1020157031658 A KR 1020157031658A KR 20157031658 A KR20157031658 A KR 20157031658A KR 102191695 B1 KR102191695 B1 KR 102191695B1
Authority
KR
South Korea
Prior art keywords
peptide
seq
ala
cancer
prt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157031658A
Other languages
English (en)
Korean (ko)
Other versions
KR20150140736A (ko
Inventor
인두 파리크
케네쓰 비. 아들러
Original Assignee
바이오마크 파마슈티칼스 리미티드
노쓰 캐롤라이나 스테이트 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오마크 파마슈티칼스 리미티드, 노쓰 캐롤라이나 스테이트 유니버시티 filed Critical 바이오마크 파마슈티칼스 리미티드
Publication of KR20150140736A publication Critical patent/KR20150140736A/ko
Application granted granted Critical
Publication of KR102191695B1 publication Critical patent/KR102191695B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Virology (AREA)
KR1020157031658A 2013-04-05 2014-04-07 전이 억제제 Expired - Fee Related KR102191695B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808966P 2013-04-05 2013-04-05
US61/808,966 2013-04-05
PCT/US2014/033206 WO2014165853A1 (en) 2013-04-05 2014-04-07 Inhibitors of metastasis

Publications (2)

Publication Number Publication Date
KR20150140736A KR20150140736A (ko) 2015-12-16
KR102191695B1 true KR102191695B1 (ko) 2020-12-16

Family

ID=51654619

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157031658A Expired - Fee Related KR102191695B1 (ko) 2013-04-05 2014-04-07 전이 억제제

Country Status (19)

Country Link
US (4) US9408886B2 (cg-RX-API-DMAC7.html)
EP (1) EP2981279B1 (cg-RX-API-DMAC7.html)
JP (1) JP6449849B2 (cg-RX-API-DMAC7.html)
KR (1) KR102191695B1 (cg-RX-API-DMAC7.html)
CN (1) CN105517562B (cg-RX-API-DMAC7.html)
AU (1) AU2014247979B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015025398A2 (cg-RX-API-DMAC7.html)
CA (1) CA2908832C (cg-RX-API-DMAC7.html)
DK (1) DK2981279T3 (cg-RX-API-DMAC7.html)
ES (1) ES2714863T3 (cg-RX-API-DMAC7.html)
HU (1) HUE043971T2 (cg-RX-API-DMAC7.html)
IL (1) IL241937B (cg-RX-API-DMAC7.html)
MX (1) MX363077B (cg-RX-API-DMAC7.html)
PL (1) PL2981279T3 (cg-RX-API-DMAC7.html)
PT (1) PT2981279T (cg-RX-API-DMAC7.html)
RU (1) RU2681213C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201708125PA (cg-RX-API-DMAC7.html)
WO (1) WO2014165853A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201508010B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2681213C2 (ru) 2013-04-05 2019-03-05 Байомарк Фармасьютикалз, Лтд. Ингибиторы метастазирования
CN108686220A (zh) * 2018-07-13 2018-10-23 刘慧荣 一种针对甲状腺癌的抗肿瘤剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
AU2002322475B2 (en) 2001-06-26 2008-02-21 North Carolina State University Blocking peptide for inflammatory cell secretion
AU2002362753B9 (en) * 2001-10-05 2008-05-15 The Trustees Of The University Of Pennsylvania Compositions for and methods of treating and preventing sirs/sepsis
DE60308251T2 (de) 2002-04-17 2007-08-30 Canon K.K. Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten
US7524926B2 (en) 2005-01-20 2009-04-28 Biomarck Pharmaceuticals, Ltd. Mucin hypersecretion inhibitors and methods of use
WO2006086681A2 (en) * 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
PT2053915E (pt) * 2006-07-26 2014-08-25 Biomarck Pharmaceuticals Ltd Peptídeos para atenuar a libertação de mediadores inflamatórios
EP2069477A4 (en) 2006-10-06 2010-12-08 Celtaxsys Inc CHEMICAL REPULSION OF CELLS
EP2078204A2 (en) * 2006-10-27 2009-07-15 George Mason Intellectual Properties, Inc. Assay for metastatic colorectal cancer
WO2009062128A2 (en) * 2007-11-08 2009-05-14 Indiana University Research And Technology Corporation Combination drug therapy for the treatment of cancer
EP2105511A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US9073974B2 (en) * 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
JP6225104B2 (ja) * 2011-04-08 2017-11-01 タフツ メディカル センター インコーポレイテッドＴｕｆｔｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ，Ｉｎｃ． ペプデューシンの設計および使用
RU2681213C2 (ru) 2013-04-05 2019-03-05 Байомарк Фармасьютикалз, Лтд. Ингибиторы метастазирования

Also Published As

Publication number Publication date
RU2015146997A (ru) 2017-05-15
CA2908832A1 (en) 2014-10-09
AU2014247979A1 (en) 2015-10-29
EP2981279A4 (en) 2016-11-09
ES2714863T3 (es) 2019-05-30
MX363077B (es) 2019-03-07
KR20150140736A (ko) 2015-12-16
US9408886B2 (en) 2016-08-09
JP6449849B2 (ja) 2019-01-09
SG10201708125PA (en) 2017-11-29
CN105517562B (zh) 2018-12-28
ZA201508010B (en) 2017-01-25
RU2015146997A3 (cg-RX-API-DMAC7.html) 2018-03-13
US20210130403A1 (en) 2021-05-06
WO2014165853A1 (en) 2014-10-09
AU2014247979B2 (en) 2018-06-28
US11466054B2 (en) 2022-10-11
US20140302057A1 (en) 2014-10-09
NZ712955A (en) 2021-03-26
US20190119320A1 (en) 2019-04-25
PL2981279T3 (pl) 2019-09-30
HUE043971T2 (hu) 2019-09-30
EP2981279A1 (en) 2016-02-10
JP2016516756A (ja) 2016-06-09
CN105517562A (zh) 2016-04-20
EP2981279B1 (en) 2018-12-19
US10683328B2 (en) 2020-06-16
MX2015014036A (es) 2016-02-25
IL241937B (en) 2019-03-31
BR112015025398A2 (pt) 2017-10-10
HK1221159A1 (en) 2017-05-26
DK2981279T3 (en) 2019-03-25
PT2981279T (pt) 2019-03-14
US10011636B2 (en) 2018-07-03
US20170121369A1 (en) 2017-05-04
RU2681213C2 (ru) 2019-03-05
SG11201508249WA (en) 2015-11-27
CA2908832C (en) 2023-01-24

Similar Documents

Publication Publication Date Title
ES2385924T3 (es) Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares
CN112135639B (zh) 细胞组装介导的癌症免疫治疗检查点抑制剂的递送
US20150132226A1 (en) Treatment of cancer
EP4292606A2 (en) Compositions for treating cancer
US11466054B2 (en) Inhibitors of metastasis
KR20240056684A (ko) 혈관활성 장 펩티드(vip) 수용체 길항제
EP2240195A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
AU2016205125A1 (en) Formulation of MK2 inhibitor peptides
JP6782932B2 (ja) Ｎｐｒ−ａアゴニストの新規用途
AU2005325227B2 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2016071431A9 (en) A combination for cancer therapy
US20200093789A1 (en) Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor
HK1221159B (en) Mareks inhibitor peptides for inhibiting metastasis
EP3581196B1 (de) Inhibitoren des transferrinrezeptor-2 zur verwendung bei der behandlung von osteoporose
WO2022076932A1 (en) Compositions and methods of treating a pi3k mediated disease
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
US10413564B2 (en) Compositions and methods for combating drug-resistant cancers
WO2025032571A1 (en) Unit dosage forms and methods comprising bl8040 for intravenous administration
KR20250154429A (ko) 암 면역요법을 위한 형질전환 성장인자-베타 슈퍼패밀리가 각인된 자연살해세포
NZ712955B2 (en) Inhibitors of metastasis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20231211

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231211